Most people who hurt their back are also dealing with something else, whether it’s a bad knee, chronic headaches, or a digestive condition that flares when stress spikes.

Yet the traditional healthcare system treats each as a separate problem, requiring a separate appointment and often a separate provider.

Hinge HealthHNGE

was built to simplify one part of that fragmented system by making musculoskeletal (MSK) care easier to access. Now, it’s betting that the same model can extend beyond joint and muscle pain to treat more of the conditions its members are already managing.

Inside Hinge’s AI Care Engine

The original MSK product traces back to 2014, when co-founders Daniel Perez and Gabriel Mecklenburg both navigated painful recoveries from separate injuries and decided the rehab experience was broken. Their shared frustration with rehab became the foundation for Hinge Health.

The company’s TrueMotion technology turns any smartphone camera into a 3D motion lab, tracking more than 100 anatomical landmarks in real time to guide patients through exercises. Its newer Movement Analysis tool measures range of motion, alignment, and endurance to generate a proprietary HingeScore.

Additionally, HingeSelect now covers the full MSK journey, from physical therapy and imaging to specialist care, surgery, and recovery, all through one platform.

The Financial Case Is Strengthening

The business model is B2B at its core. Employers, health plans, and consultants pay Hinge Health to give their populations access to the platform. Clients increased 24% year-over-year as of June 30, 2026.

Second-quarter revenue rose 53%, while free cash flow more than tripled to $99.6M. Management raised full-year revenue guidance to $856M–$860M, implying roughly 46% growth for 2026.

Wall Street is warming up to the story. Citizens raised its price target to $107 from $96 and maintained a Market Outperform rating, while Stifel lifted its target to $96 from $90 and kept its Buy rating.

Stifel also pointed to Hinge’s improving cash generation, noting that shares trade at roughly 19x free cash flow after accounting for stock-based compensation. The stock has climbed 95% this year, reflecting growing investor confidence in Hinge’s growth story.

The Gut Is the Next Frontier

Digestive conditions affect roughly one in four US adults and account for $135B in annual medical spending. Yet 69% of US counties have no gastroenterologist, leaving many patients reliant on primary care without a clear path to treatment.

Hinge Health signed a definitive agreement to acquire Cylinder Health for $105M in cash. a virtual-first digestive healthcare company. Cylinder has already treated more than 150K people. An integrated Gastrointestinal Care Program is expected to launch in a single app in 2027.

Where the Bet Gets Risky

Hinge’s expansion comes with a execution challenge. Stifel called the Cylinder acquisition unexpected, raising questions about strategic fit and whether management could lose focus while simultaneously scaling HingeSelect and its migraine offering.

Those concerns will take time to resolve. The digestive-care launch isn’t expected until 2027, meaning Hinge must integrate a new clinical program while proving that its existing expansion efforts can deliver.

However, there is a case for the strategy. Digestive conditions frequently overlap with MSK and migraine conditions, while Hinge’s existing employer relationships give new products a built-in audience. Its technology stack also allows new care programs to be added without rebuilding the platform from scratch.

The bigger risk is what investors are already paying for that opportunity. At roughly 31x forward earnings and with shares near their 52-week high, Hinge trades at a premium that leaves less room for execution mistakes.

Still, the company's track record gives investors reason to believe it can grow into those expectations.